Skip to main content

Advertisement

Log in

Clinical Trials in Youth-Onset Type 2 Diabetes: Needs, Barriers, and Options

  • Pediatric Type 2 Diabetes (PS Zeitler, Section Editor)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Youth-onset type 2 diabetes (T2D) is increasingly recognized as a disorder with substantial risk for long-term metabolic, cardiovascular, and renal morbidity and mortality, as well as individual and societal burden. Recent studies suggest that the disorder differs from adult-onset T2D in a variety of ways and that there is an urgent need for an expanded set of treatment options. However, demographic, economic, and social challenges limit the number of eligible candidates for clinical trials in youth-onset T2D, and a growing number trials mandated by regulatory agencies have created a circumstance in which too many trials are chasing too few eligible participants. A solution to this situation will require novel approaches to clinical trial design incorporating collaboration among clinical investigators, pharmaceutical sponsors, and regulatory agencies. If successful, this approach could also serve as a model for clinical trials in other rare and understudied pediatric disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cefalu W. TODAY reflects on the changing “faces” of type 2 diabetes. Diabetes Care. 2013;36:1732–4.

    Article  PubMed Central  PubMed  Google Scholar 

  2. TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–56. This article reports the primary findings of the TODAY study, the first large trial examining the efficacy of medication and lifestyle intervention in youth-onset T2D.

    Article  PubMed Central  Google Scholar 

  3. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43.

    Article  CAS  PubMed  Google Scholar 

  4. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010;33:501–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–12.

    Article  CAS  PubMed  Google Scholar 

  6. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1735–41.

    Article  PubMed Central  Google Scholar 

  7. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002;25:89–94.

    Article  CAS  PubMed  Google Scholar 

  8. Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007;30:790–4.

    Article  CAS  PubMed  Google Scholar 

  9. http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#fast. Accessed 12 Aug 2013.

  10. The Writing Group for the SEARCH for Diabetes in Youth Study Group. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716–24.

    Article  Google Scholar 

  11. Baranowski T, Cooper DM, Harrell J, Hirst K, Kaufman FR, Goran M, et al. Presence of diabetes risk factors in a large U.S. eighth-grade cohort. Diabetes Care. 2006;29:212–7.

    Article  CAS  PubMed  Google Scholar 

  12. Klingensmith GJ, Pyle L, Arslanian S, Copeland KC, Cuttler L, Kaufman F, et al. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care. 2010;33:1970–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, et al. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents: clinical practice guidelines. Pediatrics. 2013;131:364–82. Clinical Practice Guidelines from the American Academy of Pediatrics regarding the diagnosis and management of T2D in adolescents.

    Article  PubMed  Google Scholar 

  14. Zeitler P, Fu J, Tandon N, Nadeau K, Urakami T, Barrett T, et al. Type 2 diabetes in the child and adolescent. Pediatr Diabetes. 2014;15 Suppl 20:26–46. Guidelines from the International Society for Pediatric and Adolescent Diabetes regarding the diagnosis and management of T2D in adolescents.

    Article  CAS  PubMed  Google Scholar 

  15. Laffel L, Chang N, Grey M, Hale D, Higgins L, Hirst K, et al. Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. Pediatr Diabetes. 2012;13:369–75.

    Article  CAS  PubMed  Google Scholar 

  16. Hudson OD, Nunez M, Shaibi GQ. Ethnicity and elevated liver transaminases among newly diagnosed children with type 2 diabetes. BMC Pediatr. 2012;12:174.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013;70:1067–75.

    Article  PubMed  Google Scholar 

  18. Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96:159–67. This article provides in-depth information regarding the characteristics of the population with youth-onset T2D.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Bacha F, Pyle L, Nadeau K, Cuttler L, Goland R, Haymond M, et al. Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. Pediatr Diabetes. 2012;13:376–83.

    Article  CAS  PubMed  Google Scholar 

  20. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care. 2013;36:1749–57.

    Article  PubMed Central  Google Scholar 

  21. Liese AD, D’Agostino Jr RB, Hamman RF, SEARCH for Diabetes in Youth Study Group, et al. The burden of diabetes among U.S. youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006;118:1510–8.

    Article  PubMed  Google Scholar 

  22. Reinehr T, Kiess W, Kapellen T, Wiegand S, Holl RW, APV and DPV Wiss Study Group and German Competence Net Obesity. Children with diabetes mellitus type 2 in Europe: an underserved population. Arch Dis Child. 2010;95:954.

    Article  CAS  PubMed  Google Scholar 

  23. TODAY Study Group, Wilfley D, Berkowitz R, Goebel-Fabbri A, Hirst K, Ievers-Landis C, et al. Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the TODAY study. Diabetes Care. 2011;34:858–60.

    Article  Google Scholar 

  24. The United States of America Food and Drug Administration Modernization Act of 1997. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/default.htm. Accessed 6 Nov 2014.

  25. GlaxoSmithKine Clinical Trial Study Register website. http://www.gsk-clinicalstudyregister.com/study/49653/207#rs. Accessed 17 Oct 2014

  26. Food and Drug Administration Amendments Act of 2007. http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf. Accessed 6 Nov 2014

  27. Establishment of Pediatric Review Committee. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm049871.pdf. Accessed 6 Nov 2014

  28. The United States of America. Pediatric Research Equity Act of 2003. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM077853.pdf. Accessed 6 Nov 2014

  29. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Accessed 6 Nov 2014

  30. Regulation (EC) No 1902/2006, an amending regulation in which changes to the original text were introduced relating to decision procedures for the European Commission. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1902/reg_2006_1902_en.pdf. Accessed 6 Nov 2014.

  31. ClinicalTrials.gov website. Accessed 17 Oct 2014. Search term = type 2 diabetes, qualifier Child (birth-17)

  32. FDA Approved Drug Products website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 17 Oct 2014

  33. FDA Approved Drug Products website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist. Accessed 17 Oct 2014

Download references

Acknowledgments

No funding support was provided for the preparation of this manuscript from any source or sponsor.

Compliance with Ethics Guidelines

Conflicts of Interest

Philip Zeitler is a consultant and has participated in the design and monitoring of clinical trials for Daiichi-Sankyo, Bristol-Myers Squibb, and Merck.

Hubert S. Chou is an employee of Daichii-Sankyo Pharma Development and has stock in the company.

Kenneth C. Copeland is a consultant and has participated in the design and monitoring of clinical trials for Daiichi-Sankyo.

Mitchell Geffner is a consultant and has participated in the design and oversight of clinical trials for Daichii-Sankyo. Dr. Geffner is a consultant for Ipsen and on the advisory board for Merck-Serono, Novo Nordisk, Pfizer Inc, and Endo pharmaceuticals. He receives research support from Eli Lilly, Inc, Genentech, Inc, Novo Nordisk, Pfizer, Inc, and Versartis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Philip Zeitler.

Additional information

This article is part of the Topical Collection on Pediatric Type 2 Diabetes

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeitler, P., Chou, H.S., Copeland, K.C. et al. Clinical Trials in Youth-Onset Type 2 Diabetes: Needs, Barriers, and Options. Curr Diab Rep 15, 28 (2015). https://doi.org/10.1007/s11892-015-0597-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11892-015-0597-2

Keywords

Navigation